e11510 Background: Eribulin is a non-taxane, microtubule dynamics inhibitor that was approved for the treatment of patients with metastatic breast cancer (MBC) in Europe in March 2011. Experience with routine use of eribulin is limited. Methods: All patients receiving eribulin at the Oncology Department, Karolinska University Hospital outside of a clinical trial are treated according to the approved indication and dosology. For the purpose of an internal quality control, treated patients are registered in a database. All patients registered at the time point of the analysis were evaluated for safety and efficacy. Treatment toxicity including fatigue, neurotoxicity and infection was graded according to CTCAE v4.0. Efficacy was investigated using the routinely performed radiological assessments. Results: To date, twenty patients have received a total of 104 cycles of eribulin. All patients were heavily pretreated with a median of 3 (range 1-6) previous chemotherapy lines for MBC. The median age of the patients was 54 years (range 35-74). Fourteen patients are alive and 12 are still undergoing treatment with eribulin. No hypersensitivity reactions and no toxic deaths were seen. Fatigue was observed in 45% of the patients (grade 3 20%), while 20% experienced neurotoxicity and 35% were treated for an infection (grade 3 20%). None of the patients experienced grade 3 neurotoxicity. Interestingly, 3 cases of Herpes zoster reactivation were observed. Fifteen of the patients have been radiologically assessed at the time point of the analysis. Six of those patients had partial response (PR), one patient had complete response (CR) and one patient had stable disease (SD). Seven patients had progressive disease (PD). Conclusions: Eribulin administered outside of a clinical trial in patients with advanced breast cancer was safe and well tolerated. Although the majority of the patients were heavily pretreated, objective response was seen in nearly half of the cases.
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials